A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

Last updated:
2026-09-05
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PROOF-OF-CONCEPT PHASE 2A, DOUBLE-BLIND, 2-ARM TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF TWICE DAILY DELGOCITINIB CREAM 20 MG/G COMPARED WITH CREAM VEHICLE DURING A 16-WEEK TREATMENT PERIOD IN ADULT SUBJECTS WITH MILD TO SEVERE PALMOPLANTAR PUSTULOSIS

Intervention/treatment:
DELGOCITINIB
Medical condition:
PALMOPLANTAR PUSTULOSIS
Protocol code:
LP0133-2393
Control number:
296890
Status:
Recruiting
Approved:
May 08, 2025
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT07013201
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Clinical Disclosure
Role
CONTACT
Phone:
(+45) 4494 5888
Sponsor
LEO PHARMA INC

Locations

Alberta

LEO Pharma Investigational Site
Calgary, Alberta, T3A 2N1
RECRUITING
LEO Pharma Investigational Site
Edmonton, Alberta, T6W 4V4
RECRUITING

British Columbia

LEO Pharma Investigational Site
Surrey, British Columbia, V3R 6A7
RECRUITING

Manitoba

LEO Pharma Investigational Site
Winnipeg, Manitoba, R3M 3Z4
RECRUITING

New Brunswick

LEO Pharma Investigational Site
Fredericton, New Brunswick, E3B 1G9
RECRUITING

Ontario

LEO Pharma Investigational Site
Hamilton, Ontario, L8L 3C3
RECRUITING
LEO Pharma Investigational Site
Hamilton, Ontario, L8N 1Y2
COMPLETED
LEO Pharma Investigational Site
Markham, Ontario, L3P 1X2
RECRUITING
LEO Pharma Investigational Site
Waterloo, Ontario, N2J 1C4
RECRUITING

Quebec

LEO Pharma Investigational Site
Montreal, Quebec, H2X 2V1
RECRUITING
Did you find what you were looking for?